Cagrilintide is studied as a long-acting amylin analog engaging the AMY receptor family, independent of the incretin axis. Receptor pharmacology and handling for NZ research benches.
The cagrilintide peptide (development code AM833) is a synthetic amylin analog studied in vitro for its engagement of the amylin/calcitonin (AMY1/AMY2/AMY3) receptor family — a signalling axis distinct from the incretin (GIP/GLP-1) receptors. This profile is a strictly in-vitro research reference for New Zealand laboratories characterising amylin-receptor pharmacology.
What is cagrilintide?
Cagrilintide is a 37-residue peptide analog derived from native amylin, with amino-acid substitutions studied for solubility and stability, plus a C20 fatty diacid attached at a lysine residue studied for reversible albumin association in plasma-stability assays.
Cagrilintide identity and specifications
| Attribute | Value |
|---|---|
| Development code | AM833 |
| Class | Long-acting amylin analog (research reference) |
| Length | 37 amino acid residues |
| Average mass | ~3800 Da |
| Backbone origin | Native amylin with acylation |
| Receptor family studied | AMY1 / AMY2 / AMY3 (amylin/calcitonin family) |
| Format supplied | Lyophilised powder, research use only |
| Storage (lyophilised) | -20 °C, protected from moisture |
Receptor pharmacology in vitro
- Studied for selective agonism at the amylin/calcitonin receptor family (AMY1, AMY2, AMY3) in transfected cell-line assays.
- No cross-activity reported at the GLP-1 or GIP receptor systems in published binding panels — the mechanistic basis for studying it alongside GLP-1 ligands in combination-pharmacology research.
- Fatty-acid diacid modification is studied for its effect on serum albumin association and apparent in-vitro stability.
- Used as a reference ligand for amylin-receptor-selective screening distinct from incretin-receptor panels.
Amylin and GLP-1 receptor pathways studied in parallel
Because amylin and GLP-1 receptor systems do not overlap pharmacologically, cagrilintide and GLP-1 receptor ligands such as semaglutide are frequently characterised side by side in comparative in-vitro receptor-pharmacology panels, using independent reporter assays for each receptor family.
Published in-vitro and structural literature
| Research focus | Assay type | Typical readout studied |
|---|---|---|
| AMY receptor binding | Radioligand competition | IC50 / Ki |
| Receptor activation | cAMP accumulation (AMY-R cell line) | EC50 |
| Plasma protein stability | Serum incubation + LC-MS | Apparent degradation half-life |
Handling and storage reference
- Supplied as lyophilised powder for reconstitution into assay buffer for laboratory research only.
- Lyophilised material: stable at -20 °C for 24+ months when protected from moisture.
- Reconstituted working solutions: store at 2–8 °C and use within your own validated assay window.
- Avoid repeated freeze–thaw cycles to preserve assay reproducibility.
Cagrilintide vs semaglutide vs tirzepatide: receptor coverage
| Attribute | Cagrilintide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptor family studied | AMY1/2/3 | GLP-1R | GIP + GLP-1R |
| Class | Amylin analog | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Overlap with incretin receptors | None reported | N/A | N/A |
Certificate of analysis expectations
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Sourcing research cagrilintide in New Zealand
Kiwi Peps supplies cagrilintide verified to the KP-99 Purity Standard (99%+ HPLC-MS), with every batch recorded in The Batch Book. Orders cleared by 2pm NZT ship the same working day under Bench-Ready Dispatch, tracked with NZ Post CourierPost. Strictly for in-vitro research use only.
Frequently asked questions
What is cagrilintide studied for?
Cagrilintide is used in vitro as a reference ligand for the amylin/calcitonin (AMY1/AMY2/AMY3) receptor family, in receptor-binding and activation assays.
How does cagrilintide differ from semaglutide at the receptor level?
Cagrilintide engages the amylin/calcitonin receptor family; semaglutide engages the GLP-1 receptor. Published in-vitro data reports no cross-activity between the two receptor systems.
What is the molecular weight of cagrilintide?
Cagrilintide has an average molecular mass of approximately 3800 Da across its 37-residue sequence.
How is cagrilintide supplied by Kiwi Peps?
As lyophilised powder verified to the KP-99 Purity Standard, with a HPLC-MS certificate of analysis in The Batch Book.
Is cagrilintide approved for human use in New Zealand?
No. Kiwi Peps supplies cagrilintide strictly as a research-use-only peptide for in-vitro laboratory work.
